scholarly journals Negative emotions in community-dwelling adults with prediabetes and hypertension

2020 ◽  
Vol 48 (4) ◽  
pp. 030006052091841
Author(s):  
Qianling Zhuang ◽  
Lirong Wu ◽  
Wang Ting ◽  
Lin Jie ◽  
Jingying Zou ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Negative Emotions ◽  
Community Dwelling ◽  
Normal Blood ◽  
Current Status ◽  
Anxiety And Depression ◽  
Health Providers ◽  
Glucose Levels ◽  
Adult Men

Objective The purpose of this study was to investigate negative emotions and factors related to the risk of mental disorders in individuals with prediabetes and hypertension. Methods A total of 504 community-dwelling adult men and women in Suzhou, China, were enrolled and questionnaires used to obtain sociodemographic data, anxiety and depression scores, and current status of common metabolic indicators, including blood glucose level and blood pressure. Results Anxiety and depression scores in participants with prediabetes and hypertension were significantly higher than those in participants with normal blood glucose levels and normal blood pressure. Correlation analysis revealed that age, sex, smoking, duration of disease, physical activity, blood pressure and fasting plasma glucose levels were key factors accelerating the progression to both anxiety and depression in all participants. Conclusions More attention should be paid to negative emotions in individuals with prediabetes and hypertension. These findings could help to inform health providers in developing interventions for this population.

scholarly journals Overview of Glucose Levels, Blood Pressure, and Lipid Profiles in Patients with Prolanis DM Hypertension

2021 ◽  
Vol 2 (2) ◽  
pp. 61-67
Author(s):  
Hening Imawati
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Lipid Profile ◽  
Normal Blood ◽  
Primary Data ◽  
Service Program ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
High Lipid ◽  
Research Type

The Primary Clinic of UKSW is one of the FKTP BPJS Health implementing service program of chronic disease (Prolanis). Patients with screening of one time blood glucose 200 mg/dL or fasting blood sugar 126 mg/dL were included in control patients of DM prolanis. Patients with criteria of pre hypertension and hypertension 1 were included in the control patients of hypertensive prolanis. Patients with DM and hypertension may have level of high lipid profile so laboratory tests are needed to prevent complications, including cholesterol, HDL, LDL and triglycerides. Research objective to find out the description of glucose level, blood pressure, and lipid profile in patients of DM hipertension prolanis at the Primary Clinic of UKSW Salatiga. The research type was descriptive. The research data was primary data by measuring blood pressure, blood glucose levels and lipid profile. Research results normotension 16 (30,2%), pre hypertension 20 (37,70%), and first degree hypertension as many as 17 (32,10%). The glucose levels of normal blood 20 (37,74%), normal 33 (62,26%). The profile levels of normal lipid cholesterol 30 (54,72%), HDL 26 (49,06%), LDL 9 (18,98%), and triglyceride 30 (56,60%). The profile levels of abnormal lipid cholesterol 29 (45,29%), HDL 27 (50,95%), LDL 44 (83,02%), and triglyceride 23 (43,40%). The glucose levels of normal blood 20 (37,74%) in normotension 5 (9,4%), pre hypertension 8 (15,09%), and first degree hypertension as many as 7 (13,21%). Blood glucose levels normal 62,3% in normotension 11 (20,8%), pre hypertension 12 (22,64%) and first degree hypertension as many as 10 (18,87%).

Abstract 17853: Activation of AMP-activated Protein Kinase (AMPKα) by AICAR Attenuates Klotho Deficiency-induced Endothelial Dysfunction, Arterial Stiffening and Hypertension

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Yi Lin ◽  
Zhongjie Sun
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Endothelial Dysfunction ◽  
Protein Expression ◽  
Normal Diet ◽  
Collagen I ◽  
Daily Injection ◽  
Arterial Stiffening ◽  
Glucose Levels ◽  
Amp Activated Protein Kinase

Background: Arterial stiffening and hypertension are progressive aging-related disorders. Klotho (KL) is a recently-discovered anti-aging gene but its role in the pathogenesis of endothelial dysfunction, arterial stiffening and hypertension is not fully understood. Methods and Results: Heterozygous Klotho deficiency ( KL +/- ) mice and WT littermate mice were fed on high fat diet (HFD) or normal diet (ND). Plasma KL in KL heterozygeous mice (+/-) is about a half of that of the WT mice. Pulse wave velocity (PWV), an index of arterial stiffening, was increased in KL +/- mice but not in WT mice fed on HFD for 4 weeks. Systolic blood pressure and blood glucose levels were increased earlier with greater magnitudes in KL +/- mice than in WT mice fed on HFD. Notably, protein expression of collagen I, Runx2, and TGFβ1 were increased but protein expression of phosphorylated AMPKα (pAMPKα), phosphorylated eNOS (peNOS), and Mn-SOD were decreased in aortas of KL +/- mice fed on HFD for 5 weeks. Interestingly, daily injection of AICAR, an activator of AMPK, abolished the increases in PWV, blood pressure, and blood glucose in KL +/- mice fed on HFD. AICAR not only abolished the downregulation of pAMPKα, peNOS, and Mn-SOD levels but also attenuated the increased levels of collagen I, Runx2, TGFβ1 and superoxide, elastic lamellae breaks, and calcification in aortas in KL +/- mice fed on HFD. Conclusions: Klohto deficiency promotes HFD-induced endothelial dysfunction, arterial stiffening and hypertension. The promoting effects of klotho deficiency on arterial stiffening may be due to downregulation of endothelial AMPKα activity.

Testing the Associations Between State and Trait Anxiety, Anger, Sadness, and Ambulatory Blood Pressure and Whether Race Impacts These Relationships

2021 ◽  
Author(s):  
Larisa Gavrilova ◽  
Matthew J Zawadzki
Keyword(s):  
Blood Pressure ◽  
Trait Anxiety ◽  
Ambulatory Blood Pressure ◽  
Cardiovascular Health ◽  
Negative Emotions ◽  
Anxiety And Depression ◽  
Negative Effects ◽  
Conditional Effects ◽  
Potential Risk Factors ◽  
Ecological Momentary

Abstract Background Anxiety, anger, and sadness are related to elevated ambulatory blood pressure (ABP), yet it is unclear whether each emotion exerts unique effects. Moreover, an understanding of who might be most susceptible to the negative effects of these emotions is limited, with the trait tendency to experience them or one’s race as potential moderators. Purpose The study examined the potential for differential effects of momentary anxiety, anger, and sadness on ABP. The study assessed whether a trait tendency to experience these negative emotions and/or race (Black vs. non-Black) would moderate these relationships. Methods Participants (n = 153) completed trait anxiety, anger, and depressive symptoms measures at baseline. ABP was collected over two 24-hour periods 3–4 months apart. Momentary measures of anxiety, anger, and sadness were assessed via ecological momentary assessment (EMA) after each ABP reading. Results Momentary anxiety consistently predicted diastolic blood pressure but not systolic blood pressure. Momentary anger and sadness did not predict blood pressure (BP). Conditional effects were found with momentary anxiety and anger predicting elevated BP in those individuals with trait anxiety/anger at its mean. Trait anxiety and depression consistently predicted heightened BP in Black participants. Trait anger did not moderate the relationships between negative emotions and ABP. Conclusions Findings suggest that momentary anxiety and anger should be given attention as potential risk factors for hypertension and highlight the unique perspective of EMA methods. Black participants who were more anxious and depressed experienced heightened BP, with anxiety and depression providing possible intervention targets in improving racial disparities in cardiovascular health.

scholarly journals Effect of Increased Daily Water Intake and Hydration on Health in Japanese Adults

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1191 ◽  
Author(s):  
Yumi Nakamura ◽  
Hiroshi Watanabe ◽  
Aiko Tanaka ◽  
Masato Yasui ◽  
Jun Nishihira ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Body Temperature ◽  
Water Intake ◽  
Fasting Blood Glucose ◽  
Intervention Group ◽  
Glucose Levels ◽  
Daily Water Intake ◽  
Daily Water ◽  
Water Supplementation

Increased hydration is recommended as healthy habit with several merits. However, supportive data are sparse. To assess the efficacy of increased daily water intake, we tested the effect of water supplementation on biomarkers in blood, urine, and saliva. Twenty-four healthy Japanese men and 31 healthy Japanese women with fasting blood glucose levels ranging from 90–125 mg/dL were included. An open-label, two-arm, randomized controlled trial was conducted for 12 weeks. Two additional 550 mL bottles of water on top of habitual fluid intake were consumed in the intervention group. The subjects drank one bottle of water (550 mL) within 2 h of waking, and one bottle (550 mL) 2 h before bedtime. Subjects increased mean fluid intake from 1.3 L/day to 2.0 L/day, without changes in total energy intake. Total body water rate increased with associated water supplementation. There were no significant changes in fasting blood glucose and arginine vasopressin levels, but systolic blood pressure was significantly decreased in the intervention group. Furthermore, water supplementation increased body temperature, reduced blood urea nitrogen concentration, and suppressed estimated glomerular filtration rate reduction. Additionally, existence of an intestinal microbiome correlated with decreased systolic blood pressure and increased body temperature. Habitual water supplementation after waking up and before bedtime in healthy subjects with slightly elevated fasting blood glucose levels is not effective in lowering these levels. However, it represents a safe and promising intervention with the potential for lowering blood pressure, increasing body temperature, diluting blood waste materials, and protecting kidney function. Thus, increasing daily water intake could provide several health benefits.

Effectiveness of acarbose in treating elderly patients with diabetes with postprandial hypotension

2017 ◽  
Vol 65 (4) ◽  
pp. 772-783 ◽  
Author(s):  
Jie Zhang ◽  
Lixin Guo
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Elderly Patients ◽  
Controlled Trial ◽  
Clinical Trial Registry ◽  
Postprandial Hypotension ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Patients With Diabetes ◽  
Group B

Postprandial hypotension (PPH) is a common condition that occurs primarily in elderly patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the effectiveness of acarbose for PPH; it also investigated possible mechanisms behind PPH development. This single-blind, randomized controlled trial included 91 elderly patients with T2DM, aged between 60 and 80 years, who were inpatients at Beijing Hospital between March 2012 and November 2014. The patients were included into one of three groups: Group A, patients with T2DM without PPH; Group B, patients with T2DM with PPH receiving placebo; and Group C, patients with T2DM with PPH receiving acarbose. After an overnight fast, patients received a single dose of acarbose (100 mg) or placebo and then consumed a standardized 450 kcal meal. Blood pressure, glucose levels, heart rate (HR), and catecholamine levels were evaluated. Acarbose ameliorated PPH as determined by significant improvements in the duration and maximal fall in blood pressure (both p<0.001); however, no differences in HR and blood glucose levels were observed. In patients with PPH, blood pressure was correlated with blood glucose and HR variability values (p<0.05). Correlations between epinephrine and glucagon-like peptide-1 with blood pressure in groups A and C were largely lost in group B. Acarbose reduced postprandial blood pressure fluctuations in elderly patients with diabetes. PPH may be related to impaired autonomic nervous system function, reduced catecholamine secretion, and postprandial fluctuations in blood glucose levels.Trial registration numberChinese Clinical Trial Registry ChiCTR-IPR-15006177.

Sign in / Sign up

Export Citation Format

Share Document